To see the other types of publications on this topic, follow the link: Dent – transplantation.
Journal articles on the topic 'Dent – transplantation'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 48 journal articles for your research on the topic 'Dent – transplantation.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Gault, Philippe. "Transplantations des canines incluses." L'Orthodontie Française 84, no. 3 (September 2013): 221–40. http://dx.doi.org/10.1051/orthodfr/2013058.
Full textAbstract:
Les techniques de transplantation dentaire exploitent mieux que par le passé le potentiel de cicatrisation du ligament alvéolo-dentaire et réduit le risque d’ankylose-résorption radiculaire en dessous de 1,5 %. L’amélioration du pronostic qui en résulte permet d’envisager ces procédures avec plus de sérénité, et de les associer avec les traitements orthodontiques. Les transplantations peuvent offrir une solution de bonne fin lors de certaines situations cliniques difficiles à gérer autrement : ectopies, transpositions, remplacement de dents avulsées par trauma, de dents délabrées ou de dents alvéolysées par parodontites précoces, mise en place de dents incluses non-tractables, traitement des ankyloses idiopathiques. Cet article décrit les principes biologiques des transplantations avec double stimulation desmodontale, et les modalités opératoires et développe par quelques exemples le traitement de canines incluses, présentant ou non une ankylose idiopathique. L’ankylose dentaire est une fusion de l’os avec la racine. La forme idiopathique survient spontanément avant l’éruption de la dent concernée. L’étiologie n’est pas connue. La dent devenant partie du processus de remodelage osseux, elle se résorbe progressivement pour être remplacée par du tissu osseux. Ce processus est assez rapide et fragilise la dent. Aussi un diagnostic précoce permet d’envisager une transplantation dans de bonnes conditions, seul moyen permettant de rompre l’ankylose et d’obtenir une mise en place adéquate. Dans de rares cas, le point d’ankylose est accessible chirurgicalement et peut être éliminé avant de reprendre la traction orthodontique.
2
Ecotiere, L., A. Duveau, J. P. Rerolle, A. Michel, C. Poulain, C. O. Sophie, I. Etienne, I. Bouteau, F. Bridoux, and A. Thierry. "Maladie de Dent et transplantation rénale : les pièges à éviter." Néphrologie & Thérapeutique 15, no. 5 (September 2019): 393–94. http://dx.doi.org/10.1016/j.nephro.2019.07.315.
Full text
3
Marsenic, O., and B. S. Kaplan. "Hydrochlorothiazide-induced tubulointerstitial nephritis in a patient with Dent disease." Clinical Kidney Journal 2, no. 3 (March 17, 2009): 264–65. http://dx.doi.org/10.1093/ndtplus/sfp033.
Full text
4
Sekine, Takashi, Fusako Komoda, Kenichiro Miura, Junko Takita, Mitsunobu Shimadzu, Takeshi Matsuyama, Akira Ashida, and Takashi Igarashi. "Japanese Dent disease has a wider clinical spectrum than Dent disease in Europe/USA: genetic and clinical studies of 86 unrelated patients with low-molecular-weight proteinuria." Nephrology Dialysis Transplantation 29, no. 2 (September 29, 2013): 376–84. http://dx.doi.org/10.1093/ndt/gft394.
Full text
5
Gabriel, Sarah S., Hendrica Belge, Alkaly Gassama, Huguette Debaix, Alessandro Luciani, Thomas Fehr, and Olivier Devuyst. "Bone marrow transplantation improves proximal tubule dysfunction in a mouse model of Dent disease." Kidney International 91, no. 4 (April 2017): 842–55. http://dx.doi.org/10.1016/j.kint.2016.11.016.
Full text
6
Copelovitch, Lawrence, Martin A. Nash, and Bernard S. Kaplan. "Hypothesis: Dent Disease Is an Underrecognized Cause of Focal Glomerulosclerosis." Clinical Journal of the American Society of Nephrology 2, no. 5 (August 8, 2007): 914–18. http://dx.doi.org/10.2215/cjn.00900207.
Full text
7
Wang, Xiangling, Franca Anglani, Lada Beara-Lasic, Anila J. Mehta, Lisa E. Vaughan, Loren Herrera Hernandez, Andrea Cogal, et al. "Glomerular Pathology in Dent Disease and Its Association with Kidney Function." Clinical Journal of the American Society of Nephrology 11, no. 12 (October 3, 2016): 2168–76. http://dx.doi.org/10.2215/cjn.03710416.
Full text
8
Gueye, S., and D. Chauveau. "Maladie de Dent : à propos de quatre observations adultes suivis dans le département de néphrologie et de transplantation d’organes de Toulouse." Néphrologie & Thérapeutique 11, no. 5 (September 2015): 388–89. http://dx.doi.org/10.1016/j.nephro.2015.07.375.
Full text
9
Vinnakota, Dileep Nag, V. Vijay Sankar, Naveen Chirumamilla, and V. Vamsikrishna Reddy. "Osseointegrated Silicone Finger Prosthesis using Dental Implants: A Renovated Technique." Journal of Contemporary Dental Practice 15, no. 6 (2014): 818–20. http://dx.doi.org/10.5005/jp-journals-10024-1624.
Full textAbstract:
ABSTRACT Aim and background In clinical practice, we come across patients with traumatically amputated or congenitally missing partial or complete fingers that can be restored using microsurgical replantation or transplantation procedures. However, in some cases this might not be possible due to systemic or local factors and the lost or missing part has to be replaced prosthetically to offer psychological and functional wellbeing. These prostheses can be constructed with various materials like acrylics or silicone retained with the help of auxiliary aids. However, these prostheses cause some hindrance in performing functions like writing, typing, etc. The aim of the present trial was to ameliorate the existing design of implant supported finger prosthesis. Technique Distal phalange of middle finger replaced with implant supported silicone finger prosthesis is modified by utilizing a metal framework to support silicone material to improve rigidity while working. Conclusion and clinical significance We could achieve a good function, esthetics and tactile sensibility with this modified design. Whenever, feasible this design can improve the performance and patients feel a deep sense of satisfaction and improved self-esteem with this modified prosthesis. How to cite this article Vinnakota DN, Sankar VV, Chirumamilla N, Reddy VV. Osseointegrated Silicone Finger Prosthesis using Dental Implants: A Renovated Technique. J Contemp Dent Pract 2014;15(6):818-820.
10
Tair, Jawad A. Abu, and Ahmad Rahhal. "Tooth Autotransplantation in Orthodontic Patients." Journal of Contemporary Dental Practice 11, no. 3 (2010): 63–70. http://dx.doi.org/10.5005/jcdp-11-3-63.
Full textAbstract:
Abstract Aim The aims of this report are to present three cases of autotransplantation along with a review of the indications, selection criteria for patient donor and recipient sites, and the major steps in the surgical procedure. Background Autogenous tooth transplantation, or autotransplantation, is the surgical movement of a tooth from one location in the mouth to another in the same individual. It can be a good treatment option in many cases if the dentist knows the implications, indications, and contraindications. Case Descriptions Three cases with different treatment indications and plans are presented. All showed autotransplantation of teeth as part of orthodontic treatment. It emphasized the benefits of this treatment modality such as new bone formation and lower costs. One case, a rare example of multiple congenitally missing teeth treated by autotransplantation, also was presented. Summary As shown in these case reports, there are instances where the autotransplantation of teeth is appropriate and may possibly simplify future planned orthodontic or prosthodontic treatment. Clinical Significance Tooth autotransplantation is an easy and good treatment option, applicable in a lot of cases, substituting different types of prostheses, including dental implants. Citation Abu Tair JA, Rahhal A. Tooth Autotransplantation in Orthodontic Patients. J Contemp Dent Pract [Internet]. 2010 May; 11(3):063-070. Available from: http://www.thejcdp. com/journal/view/volume11-issue3-abu_tair.
11
Kulkarni, Varun. "Toothbrush: A Favorable Media for Bacterial Growth." International Journal of Experimental Dental Science 2, no. 1 (2013): 27–28. http://dx.doi.org/10.5005/jp-journals-10029-1035.
Full textAbstract:
ABSTRACT Introduction In this era of stem cell transplantation, tissue engineering and piezosurgery, it is important to consider the toothbrush as a source of potential pathogens. As toothbrush plays an important everyday role for personal oral hygiene and effective plaque removal. Oral cavity incubates diversity of microorganisms; therefore it is not surprising that some of these microorganisms were transferred to toothbrush during use. Presence of nutrients, epithelial debris and oral secretions make the toothbrush a favorable media for numerous bacterial growths. Aim The main aim of this study was to evaluate the microbial flora predominantly present in toothbrushes. Materials and methods Samples of 150 different used toothbrushes from healthy population were taken randomly for microbial analysis. Samples of toothbrushes were put in Robertson cooked meat (RCM) media for both aerobic and anaerobic microbial recognition. Inoculation was done on blood agar and MacConkey's agar plate and culture plates were incubated for 24 hours. Results Fifty-four samples showed facultative anaerobes growth, i.e. Streptococcus mutans, Alpha-hemolytic streptococci, coagulase negative Staphylococci (CONS) and diphtheroids. Sixty-six samples showed polymicrobial etiology and 30 showed purely anaerobic bacteria, i.e. Bacteroides, Lactobacilli. Conclusion Toothbrush is thus considered a potential biohazard for reintroduction of microorganisms in the oral cavity. New oral hygiene devices like Dental Air Force home dental cleaning system will emerge as true alternative for toothbrush. How to cite this article Saini R, Kulkarni V. Toothbrush: A Favorable Media for Bacterial Growth. Int J Experiment Dent Sci 2013;2(1):27-28.
12
Güler, Berceste, Büşra Terzioğlu, Banu Çukurluöz Bayındır, and Gülen Dal. "Dental implant failure in immunosuppressed renal transplant patient: A case report." International Dental Research 12, no. 3 (December 31, 2022): 171–75. http://dx.doi.org/10.5577/intdentres.2022.vol12.no3.10.
Full textAbstract:
Background: In the literature, the dental implant survival rate has been reported one hundred percent in immunosuppressed patients after a solid organ transplant (SOT). There is no previously published dental implant failure that has been reported on immunosuppressed renal transplant, which is the most common SOT therapy. Case Report: The case presented is that of a 66-years old male edentulous patient suffering from lack of functional prosthesis and who received a renal transplant two years ago. No complications such as infection, radiolucency, or pus were detected after two dental implants were placed in the mandible and after three months recovery period. The right mandibular dental implant failure occurred due to compression of the dental implant and healing head during the delivery of the patient’s removable prosthesis. Following implant socket healing after two months, the 4.8 mm diameter implant was placed immediately after. Osseointegration was completed uneventfully, and the patient was successfully rehabilitated with a two implant-retained mandibular overdenture prosthesis. The implant restoration was performing well with stable Peri-implant bone levels have shown minimal marginal bone loss at a 2-year follow-up. Conclusion: Treatment of combined immunosuppressive medication used in renal transplant patients after dental implant rehabilitation, as well as accompanying chronic diseases, should be performed considering the possibility of failure in dental implant applications. In this case report, the causes of implant failure were reported patients who received dental implant treatment after renal transplantation from a cadaver. How to cite this article: Güler B, Özaltun B, Çukurluöz Bayındır B, Dal G. Dental implant failure in immunosuppressed renal transplant patient: A case report. Int Dent Res 2022;12(3):171-5. https://doi.org/10.5577/intdentres.2022.vol12.no3.10 Linguistic Revision: The English in this manuscript has been checked by at least two professional editors, both native speakers of English.
13
Fernando, Sancia, Vinya Ravindra, and Mahesh Kumar. "Complications after autotransplantation of a maxillary canine: a case report and literature review." Dental Update 50, no. 4 (April 2, 2023): 261–64. http://dx.doi.org/10.12968/denu.2023.50.4.261.
Full textAbstract:
Autotransplantation is the positioning of a tooth in the same individual, from a donor site to an extraction site or a surgically prepared socket. A case report involving a previously transplanted maxillary canine, which later presented with complications, is discussed. We explore the indications, surgical planning and technique, associated risk factors and long-term outcomes for the transplantation of canines. CPD/Clinical Relevance: Understanding the indications and surgical requirements for canine transplantation should optimise case selection and complication management.
14
Burke, Suzanne, Andrew J. Kwasnicki, and J. Avril Macpherson. "Dental management during stem cell transplantation." Dental Nursing 10, no. 1 (January 2014): 25–29. http://dx.doi.org/10.12968/denn.2014.10.1.25.
Full text
15
Brock, Gareth. "Xerostomia and chronic oral complications among patients treated with haematopoietic stem cell transplantation." Dental Nursing 6, no. 1 (January 2010): 8–10. http://dx.doi.org/10.12968/denn.2010.6.1.46275.
Full text
16
Burbridge, Lucy, Ben Ol Cole, Ross S. Hobson, and Richard R. Welbury. "Auto-transplantation in the Restorative Management of Traumatized Anterior Teeth: A Case Report." Dental Update 32, no. 9 (November 2, 2005): 529–34. http://dx.doi.org/10.12968/denu.2005.32.9.529.
Full text
17
Jablonski, Rachael Y., Bethany Rushworth, and Kathryn A. Durey. "The multifactorial aetiology of gingival overgrowth: a case report illustrating diagnosis and management." Dental Update 46, no. 7 (July 2, 2019): 662–71. http://dx.doi.org/10.12968/denu.2019.46.7.662.
Full textAbstract:
Gingival overgrowth is the enlargement of gingival tissues and has various underlying aetiological factors. This case report highlights the multifactorial aetiology of gingival overgrowth for a patient who was prescribed an immunosuppressive strategy following renal transplantation, had poor levels of oral hygiene and a diet deficient in fruit and vegetables. The report highlights the importance of a detailed assessment to identify all underlying factors and demonstrates how a referral to the specialist services for gingival overgrowth led to a diagnosis of vitamin C deficiency. It also illustrates how both patient engagement and a conservative cause-related therapy can achieve a satisfactory resolution without any surgical intervention. CPD/Clinical Relevance: This case report highlights the importance of a detailed assessment to diagnose all relevant underlying aetiological factors involved in the development of gingival overgrowth. It also illustrates how both patient engagement and a conservative cause-related therapy can achieve a satisfactory resolution of gingival overgrowth without any surgical intervention.
18
Levina, O. A., A. K. Evseev, M. Sh Khubutiya, A. V. Babkina, and A. K. Shabanov. "Hyperbaric oxygenation in transplantology." Transplantologiya. The Russian Journal of Transplantation 12, no. 1 (March 18, 2020): 28–41. http://dx.doi.org/10.23873/2074-0506-2020-12-1-28-41.
Full textAbstract:
The ability to eliminate any form of oxygen debt by transporting oxygen to organs and tissues, by dissolving it in body fluids, brings hyperbaric oxygenation to a new level of application in transplantology. The review discusses the pathophysiological aspects of hyperbaric oxygenation during ischemia and reinfusion, especially when used in transplantology, and also investigations on the use of hyperbaric oxygenation in model experiments and in clinical practice. Analysis of the efficacy of hyperbaric oxygenation therapy at various stages of the transplantation process (preconditioning, donation, organ storage, in the early and late post-transplant periods) allows us to conclude that this method should be more widely involved in transplantation practice.Authors declare no conflict of interest.
19
Bourkas, Sophia, and Marie Achille. "The Psychosocial Adjustment of Kidney Recipients in Canada's Kidney Paired Donation Program." Progress in Transplantation 32, no. 1 (December 7, 2021): 35–40. http://dx.doi.org/10.1177/15269248211064881.
Full textAbstract:
Introduction: Kidney paired donation programs have been implemented globally. The involvement of at least 2 donors in these programs might exacerbate recipients’ debt of gratitude and guilt, worries about the donor's health, and worries about graft failure documented by previous studies. However, there is an absence of research on the psychosocial implications of kidney paired donation. This study aimed to provide an in-depth examination of recipients’ experience of kidney paired donation, with a focus on psychosocial adjustment. Methods/Approach: Individual interviews were conducted with 8 recipients who received a transplant through Canada's Kidney Paired Donation program. Data was analyzed using Interpretative Phenomenological Analysis. Findings: Four themes emerged: (a) an emotionally charged relationship with the known donor, (b) optimal distance regulation in the relationship with the anonymous donor, (c) kidney paired donation as a series of ups and downs, and (d) multilayered gratitude. Discussion: Findings are considered in relation to extant literature. Issues relevant to the transplant community's clinical and research efforts to provide kidney recipients responsive care are discussed.
20
KIRIMLIOĞLU, Nurdan, and Ömür ELÇİOĞLU. "The Viewpoints of Law and Medical Faculty Students on Organ Donation and Transplantation: A Study in Turkey." Turkiye Klinikleri Journal of Medical Sciences 30, no. 3 (2010): 829–37. http://dx.doi.org/10.5336/medsci.2008-9639.
Full text
21
K, Devibooma. "Records of Hero Stone in Sangam Literature." International Research Journal of Tamil 4, SPL 2 (February 28, 2022): 302–7. http://dx.doi.org/10.34256/irjt22s247.
Full textAbstract:
News about transplantation in Sangam literature is widely included in all texts. Nadukal (stele) performed his heroic deeds in the war, understood the war and was taken to the chest-wounded dead. The article makes it clear that the primary reason for the transplant was that Yathen was in a position to give the impression that the dead were living with them. The article goes on to explain that the performance of Nadukal worship is an expression of heroism and is considered to be the primary debt paid by the warriors to the Veeramanaram Eidyas. The article is located in the Sangam literature to illustrate the way in which Nadukal has continued in Tamil culture for a long time.
22
Itkin, G. P., A. I. Syrbu, A. P. Kyleshov, A. S. Buchnev, and A. A. Drobyshev. "Evaluation of the efficiency of a new pulsatile flow‑generating circulatory-assist system in rotary blood pumps. Research on a mathematical model." Russian Journal of Transplantology and Artificial Organs 23, no. 4 (November 12, 2021): 73–78. http://dx.doi.org/10.15825/1995-1191-2021-4-73-78.
Full textAbstract:
Objective: to study the effect of a pulsatile flow-generation (PFG) device on the basic hemodynamic parameters of the circulatory system using a mathematical model.Results. Modelling and simulation showed that the use of PFG significantly (76%) increases aortic pulse pressure. The proposed mathematical model adequately describes the dynamics of the circulatory system and metabolism (oxygen debt) on physical activity in normal conditions and heart failure, and the use of non-pulsatile and pulsatile circulatory-assist systems. The mathematical model also shows that the use of PFG device blocks the development of rarefaction in the left ventricular cavity associated with a mismatch of blood inflow and outflow in diastolic phase when there is need to increase systemic blood flow by increasing the rotary pump speed.
23
Kobayashi, Hironori, Norihiko Yoshimura, Takashi Ushiki, Yasuhiko Shibasaki, Masato Moriyama, Jun Takizawa, Miwako Narita, Hirohito Sone, and Masayoshi Masuko. "Imaging of Body Iron Stores in Transfusion-Dependent Patients By Liver Dual- Energy CT." Blood 124, no. 21 (December 6, 2014): 2677. http://dx.doi.org/10.1182/blood.v124.21.2677.2677.
Full textAbstract:
Abstract [Background] Chronic red blood cell transfusions, leading to iron overload, cause hepatic, cardiac, and endocrine dysfunction. It is very important to monitor body iron stores and to start optimal iron chelation therapy. Serum ferritin, which is widely used as a surrogate marker of body iron stores, elevate under inflammation or liver injury. Therefore, reliable techniques to evaluate body iron stores are needed. The liver iron concentration (LIC) is thought to be an indicator of total body iron stores and measurement of the T2* value by MRI has been a standard noninvasive technique to evaluate LIC. It should be worthwhile using CT, which is lower cost and widely applied in clinical setting. Dual-energy CT (DECT) is a technique to obtain additional information regarding tissue composition compared with what single-energy CT can provide. This technique is based on the fact that substances show different densities by two different energies. However, the role of DECT in monitoring LIC remains to be clarified. We examined whether a DECT could be a new technique for the measurement of LIC. [Patients and Methods] Eight transfusion-dependent patients underwent DECT. Patient 1 was a 54-year-old male with MDS (RCMD-RS). He received 66 U red blood cell transfusions in our hospital, and depended on transfusion in another hospital, but the total doses were not available. Patient 2 was a 37-year-old male with AML in 2nd relapse. His total red blood cell transfusions were 54 U. Patient 3 was a 66-year-old female with AML with MRC in 1st CR. She received 37 U red blood cell transfusions in our hospital, and depended on transfusion in another hospital, but total doses were not available. Patient 4 was a 47-year-old female who had received renal transplantation for chronic renal failure. She received 12 U red blood cell transfusions in our hospital, and had a long history of transfusion dependence in another hospital, but total doses were not available. Patient 5 was a 57-year-old male with MDS (RCMD). His total red blood cell transfusions were 148 U, and he received iron chelation therapy. Patient 6 was a 65-year-old male with AML with MRC. His total red blood cell transfusions were 82 U, and he received iron chelation therapy. Patient 7 was a 47-year-old male with AML in 3rd CR. He received 28 U red blood cell transfusions in our hospital, and depended on transfusion in another hospital, but total doses were not available. Patient 8 was a 52-year-old female with AA. Her total blood cell transfusions were 92 U. [Results] All patients were examined for serum ferritin and patients 1, 3, 4, 6, 7, and 8 also underwent liver MRI. Serum ferritin levels of patients 1, 3, 4, 6, 7, and 8 were 961, 2168, 7875, 795, 1921, and 5104 ng/ml, respectively. These patients showed hypointensity on MRI T2*-weighted images, and also showed liver iron deposition by DECT. Serum ferritin of patient 5 was 4042 ng/ml, and he showed liver iron deposition by DECT. Serum ferritin of patient 2 was 6113 ng/ml, and he did not show liver iron deposition by DECT. [Conclusion] Our results suggest that liver DECT could visualize liver iron deposition of transfusion-dependent patients and could be a new technique for the measurement of LIC instead of MRI. Disclosures No relevant conflicts of interest to declare.
24
Kobayashi, Hironori, Norihiko Yoshimura, Takayuki Katagiri, Takashi Ushiki, Kyoko Fuse, Yasuhiko Shibasaki, Miwako Narita, Hirohito Sone, and Masayoshi Masuko. "Evaluation of Liver Iron Deposition in Transfusion-Dependent Patients By Dual-Energy CT." Blood 128, no. 22 (December 2, 2016): 3619. http://dx.doi.org/10.1182/blood.v128.22.3619.3619.
Full textAbstract:
Abstract [Introduction] The launch of the oral iron chelator "Deferasirox" has improved the outcomes of blood transfusion-dependent patients with iron overload in the last decade. Although serum ferritin (SF) remains the mostly commonly used metric to monitor body iron stores for decisions regarding the indication of iron chelate therapy, it is known to be affected by many factors. The liver iron concentration (LIC) is considered to be an indicator of total body iron stores, and the MR imaging-based R2 technique is the standard non-invasive technique used to evaluate LIC. However, this technique is not used in every institution due to some limitations such as its high cost and the requirement for special software. Although the application of CT, which is easy to use and inexpensive, needs to be considered for the evaluation of LIC, the use of conventional single energy CT (SECT) to measure LIC is also limited by normal variations in CT attenuation, predominantly in patients with mild iron overload. Moreover, SECT fails to detect iron in fatty livers, which has an inverse effect on attenuation by lowering CT numbers. Dual-energy CT (DECT) is a technique that is employed to obtain precise information on tissue composition and may be useful for monitoring LIC. It is based on substances showing different densities with two different energies, with each substance displaying its own energy-dependent change in CT attenuation. The role of DECT in monitoring LIC has not yet been clarified in blood transfusion-dependent patients with iron overload. We herein evaluated iron deposition in the livers of blood transfusion-dependent patients using DECT. [Patients and Methods] Seventeen blood transfusion-dependent patients underwent liver DECT using a dual-source 128-slice CT system, and SF levels were measured at same time. DECT images were acquired using a tube voltage pair of 140 kV and 80 kV or 140 kV and 100 kV, and the three-material decomposition of fat, soft tissue, and iron. [Results] The median age of patients was 52 years (range, 25 to 66), and 8 patients were male. Eight patients with AML, 3 with MDS, and 1 each with ALL, lymphoma, aplastic anemia, Evans syndrome, congenital dyserythropoietic anemia, and chronic renal failure underwent DECT. Nine patients had undergone stem cell transplantation before DECT, and 3 were receiving iron chelate therapy. The total number of units of blood transfused was available in 11 out of 17 patients. The median number of units given was 66 (range, 36 to 150). The median SF level was 2346 ng/ml (range, 569 to 7875). We divided patients into three groups based on SF levels: high >3000 ng/ml, intermediate 1000~3000 ng/ml, low <1000 ng/ml. Five patients were classified into the high SF group (range, 3765-7875 ng/ml), 8 into the intermediate SF group (1645-2916), and 4 into the low SF group (569-1240). Four patients in high, 4 in the intermediate, and 2 in the low SF groups showed diffuse iron deposition in the liver on DECT images. One patient in the high, 2 in the intermediate, and 2 patients in the low SF groups showed focal iron deposition in the left lobe of the liver. On the other hand, two patients in the intermediate SF group did not show iron deposition on DECT images. We then divided patients into two groups based on the number of units of blood transfused: 6 patients were classified into the high unit group (range, 66-150 units), and 5 into the low unit group (36-60). Four patients in the high unit and 3 in the low unit groups showed diffuse iron deposition in the liver on DECT images. Two patients in the high unit and 1 in the low unit groups showed focal iron deposition in the left lobe of the liver. One patient in the low unit group did not show iron deposition. [Conclusion] Discrepancies between SF levels and DECT images indicate that DECT is a useful technique for the accurate evaluation of LIC, and the detection of focal iron deposition in the liver may be useful for optimizing iron chelation therapy. Disclosures No relevant conflicts of interest to declare.
25
Hashemi, Sepehr, Mehran Armand, and Chad R. Gordon. "Development and refinement of computer-assisted planning and execution system for use in face–jaw–teeth transplantation to improve skeletal and dento-occlusal outcomes." Current Opinion in Organ Transplantation 21, no. 5 (October 2016): 523–29. http://dx.doi.org/10.1097/mot.0000000000000350.
Full text
26
Banerjee, Rahul, Ann A. Lazar, Chloe Ryan, Jen Knoche, Kelly Jean Brassil, Lindsey Jackson, Dhiren Patel, et al. "Randomized Study of Digital Life Coaching during Autologous Stem Cell Transplantation." Blood 138, Supplement 1 (November 5, 2021): 4023. http://dx.doi.org/10.1182/blood-2021-147125.
Full textAbstract:
Abstract BACKGROUND: Autologous stem cell transplantation (ASCT) for multiple myeloma (MM) entails sudden life changes including acute symptom burden, changes in physical function, and shifting caregiver dynamics. Several studies have shown that anxiety, insomnia, and distress rise in the initial weeks following ASCT before slowly recovering. Long-term consequences of these acute exacerbations include persistent quality of life (QOL) impairments (El-Jawahri 2016), post-traumatic stress disorder (Griffith 2020), and the usage of potentially inappropriate medications (PIMs) for symptom management (Banerjee 2021). We have recently completed a pilot study of digital life coaching (DLC), whereby life coaches work with patients via phone calls and text messages to provide longitudinal support, education, and accountability to meet wellbeing-related goals. Our pilot study of 15 patients demonstrated the feasibility of DLC during this period, with bidirectional patient-coach engagement occurring every 5-7 days even during index hospitalizations for ASCT (Banerjee 2021). Based on these positive results, we have now launched a randomized Phase 2 study of DLC versus usual care among patients with MM undergoing ASCT. STUDY DESIGN: Our study is registered at clinicaltrials.gov as NCT04589286. We plan to enroll 60 adult patients with MM undergoing first ASCT at our institution. Inclusion criteria include English language proficiency and ownership of a personal cellphone. However, neither smartphones nor specific mobile apps are required for study participation. All patients, including those in the control arm, receive brief wellness-related tips with each request for PRO data as outlined below. As shown in the Figure, patients in the DLC arm are paired with a trained life coach beginning at Day -10 before ASCT. Coaches use structured frameworks to assist patients longitudinally with identifying and accomplishing wellbeing-related goals. Specific coaching topics can vary from week to week and are set by each patient. In addition to weekly coach-led phone calls, patients are encouraged to maintain bidirectional communication via phone/text/email as often as desired. Patients in the control arm do not receive access to DLC. Our primary endpoint is the total usage of sedative-class PIMs - including lorazepam, temazepam, zolpidem, and other similar medications - prescribed for anxiety or insomnia during each of 4 four-week study subperiods identified in the Figure. Secondary endpoints include patient-reported outcome (PRO) assessments of QOL (PROMIS Global Health), distress (NCCN Distress Thermometer), and insomnia (PROMIS Sleep Disturbances 4A). PRO assessments are collected exclusively using automated REDCap emails every 1-2 weeks as shown in the Figure. PROGRESS TO DATE: As of the data cutoff (7/31/21), 19 patients have enrolled onto our study and 5 have completed all follow-up. The median age of enrolled patients is 62 (range: 31-77), with 26% of patients aged 70 or older. As shown in our pilot study (Banerjee 2021), PRO collection via automated REDCap emails is feasible. Specifically, of 93 email-based requests for PRO assessments as of the data cutoff, 92 (99%) have been completed. Analyses of PRO assessment responses and PIM usage will be conducted after study completion. DISCUSSION: Improving patient wellbeing during the acute peri-ASCT period is an unmet need in multiple myeloma. Published supportive strategies during this time include music therapy (Bates 2017), acupuncture (Deng 2018), palliative care (El-Jawahri 2017), and programmed hospital room lighting (Valdimarsdottir 2018). DLC may offer unique advantages given its easy accessibility and unified patient-facing interface across hospital/clinic/home transitions. These strengths may be particularly relevant in light of the COVID-19 pandemic, where home-based follow-up after ASCT has become more common. That being said, broadening the accessibility of DLC to include patients with limited English proficiency or patients without personal cell phones are important priorities for future studies. In summary, our randomized Phase 2 study of DLC versus usual care is ongoing. If shown to reduce PIM prescription rates while improving wellbeing-related PRO trajectories longitudinally, DLC may become a standard of care for patients with hematologic malignancies undergoing ASCT. Figure 1 Figure 1. Disclosures Banerjee: Pack Health: Research Funding; SparkCures: Consultancy; Sanofi: Consultancy. Knoche: Amgen: Honoraria. Brassil: Abbvie: Research Funding; Astellas: Research Funding; BMS: Research Funding; Daiichi Sankyo: Research Funding; Genentech: Research Funding; GSK: Research Funding; Sanofi: Research Funding; Pack Health: Current Employment. Jackson: Pack Health: Current Employment. Patel: Pack Health: Current Employment. Lo: Oncopeptides: Consultancy; EUSA Pharma: Consultancy. Chung: Caelum: Research Funding. Wong: Amgen: Consultancy; Genentech: Research Funding; Fortis: Research Funding; Janssen: Research Funding; GloxoSmithKlein: Research Funding; Dren Biosciences: Consultancy; Caelum: Research Funding; BMS: Research Funding; Sanofi: Membership on an entity's Board of Directors or advisory committees. Wolf: Adaptive Biotechnologies: Consultancy; Teneobio: Consultancy; Sanofi: Consultancy; Amgen: Consultancy. Martin: Oncopeptides: Consultancy; Sanofi: Research Funding; Amgen: Research Funding; Janssen: Research Funding; GlaxoSmithKline: Consultancy. Shah: Bluebird Bio: Research Funding; GSK: Consultancy; Janssen: Research Funding; Indapta Therapeutics: Consultancy; BMS/Celgene: Research Funding; CareDx: Consultancy; CSL Behring: Consultancy; Kite: Consultancy; Nektar: Research Funding; Karyopharm: Consultancy; Amgen: Consultancy; Oncopeptides: Consultancy; Poseida: Research Funding; Precision Biosciences: Research Funding; Sanofi: Consultancy; Sutro Biopharma: Research Funding; Teneobio: Research Funding.
27
Shen, Chao, Yue Sheng, Rui Su, Xiaolan Deng, Sean Robinson, Zhe Yin, Lei Dong, et al. "ALKBH5 Functions As an Oncogene in Acute Myeloid Leukemia." Blood 132, Supplement 1 (November 29, 2018): 3910. http://dx.doi.org/10.1182/blood-2018-99-118988.
Full textAbstract:
Abstract N6-methyladenosine (m6A), the most abundant internal modification in eukaryotic messenger RNAs (mRNAs) has been shown to play important roles in diverse cellular and pathological processes (Deng X, et al. Cell Res. 2018;28:507-517). ALKBH5, recently identified as a m6A demethylase, was reported to promote tumorigenesis and proliferation in glioblastoma stem-like cells (GSCs) (Zhang, S. et al. Cancer Cell. 2017;31:591-606) and breast cancer stem cells (BCSCs) (Zhang, C et al. PNAS. 2016;113: E2047-E2056). While ALKBH5 is well-recognized to function as an oncogene in solid tumors, it was reported that shallow/deep deletion of ALKBH5 is associated poor prognosis in patients with acute myeloid leukemia (AML), and is frequently co-existing with TP53 mutation (Kwok, C. T et al. J Hematol Oncol. 2017; 10(1): 39), implying that ALKBH5 may function as a tumor suppressor in AML. Thus, a systematic investigation of the definitive role of ALKBH5 in AML is warranted. To this end, we performed series of in vitro and in vivo experiments to determine the function of ALKBH5 in AML. For the in vitro experiments, we used three lentiviral shRNAs (shALKBH5-A, shALKBH5-D and shALKBH5-E) to deplete ALKBH5 expression in three human AML cell lines with different TP53 mutation status: NOMO-1 (TP53-mutant), MV4;11 (TP53-WT) and MA9.3 cells (TP53-WT). Somewhat surprisingly, ALKBH5 depletion significantly (p<0.05) inhibited AML cell proliferation/growth in all three AML cells lines, regardless of the status of TP53 mutation. We next conducted colony forming assays and found that ALKBH5 knockdown significantly (p<0.01) impaired the colony forming ability to 18% ~45% of the control group level in all three AML cell lines. We further showed that ALKBH5 depletion caused a significant increase in apoptosis (with a 1.5 ~ 4 fold increase; p<0.001) in all three AML cell lines, which is consistent with the previous report that knockout of ALKBH5 caused severe apoptosis of mouse testis cells (Zheng G et al. Mol Cell. 2013; 49:18-29). In contrast, ALKBH5 knockdown did not significantly affect cell cycles. To further confirm ALKBH5's role in AML development in vivo. We utilized Xenografted AML model as well as mouse bone marrow transplantation (BMT) model. Consistent with the in vitro results, we found that NSGS mice xeno-transplanted with MV4;11-ALKBH5-knockdown cells survived significantly longer than those with MV4;11 control cells (p<0.001). Moreover, we have also conducted mouse bone marrow transplantation (BMT) assays with MLL-AF9-transduced mouse bone marrow lineage negative (Lin-) progenitor cells collected from mice carrying Alkbh5 wild-type (Alkbh5+/+), or heterozygous (Alkbh5+/-) or homozygous (Alkbh5-/-) deletion. Consistent with the xeno-transplanted mouse model results, our BMT assays also showed that Alkbh5 depletion significantly inhibited leukemogenesis and prolonged survival in BMT recipient mice (median survival of ALKBH5wt/wt +MA9 vs. ALKBH5+/- +MA9 or ALKBH5-/- +MA9: 32 days vs. 64 days or 68 days; p<0.005). Taken together, our in vitro and in vivo functional studies data indicate ALKBH5 also functions as an oncogene in AML regardless of TP53 mutation status, similar to its role in solid tumors. We are currently conducting as series of studies to reveal the molecular mechanism(s) underlying the oncogenic role of ALKBH5 in AML. Disclosures No relevant conflicts of interest to declare.
28
Leu, Jia-Shiun, Hui Deng, Han Nhat Tran, Jose Maria Salazar, Jose A. Maldonado, Carlo D. Cristobal, Xiong Wei, et al. "Abstract 2948: A humanized therapeutic antibody against S100A4 as a novel immune modulator and an inhibitor of cancer metastasis." Cancer Research 83, no. 7_Supplement (April 4, 2023): 2948. http://dx.doi.org/10.1158/1538-7445.am2023-2948.
Full textAbstract:
Abstract Widespread cancer metastasis still contributes to ~ 90% of cancer-related deaths, and limited progress has been made in treating the metastatic disease. S100A4 is a highly conserved protein and has been demonstrated to promote cancer metastasis and stemness in multiple cancer types. Furthermore, our recent single cell RNA-sequencing analysis of cancer and stromal cells in human gliomas showed that S100A4 is expressed in both cancer and immune cells to promotes immune suppressive tumor microenvironment. Significantly deleting S100A4 function in stromal cells alone was sufficient to reverse the immune phenotypes of glioma associated T cells and myeloid cells, and resulted in significantly extend survival of two different mouse glioma models. Consistently, higher S100A4 expression is also associated with poor outcomes in many cancer types. Together these observations suggest that S100A4 is a promising therapeutic target for multiple cancer types, and we developed and characterized a blocking antibody against human S100A4. We have screened 114 monoclonal antibodies against S100A4 using S100A4-induced chicken neurite outgrowth ex vivo as a functional assay. Seven of the 114 monoclonals showed significant suppressive activity ex vivo and were selected for further analysis for their in vivo activity. We chose two well-characterized breast cancer metastasis models for in vivo screening: MMTV-PyMT spontaneous and 4T1 orthotopic transplantation tumor models. One of the clones, 4-11, showed the most consistent and dramatic lung metastasis suppressive activity in both models. To identify the potential mechanisms of action since the blocking antibody is anticipated to only affect soluble S100A4 function, we focused on potential immune modulatory effect, based on our own study and those of others. We performed flow cytometry to analyze the immune phenotypes in blood, bone marrow, spleen, breast tumor, and lung metastases. In S100A4-11 treated mice, circulating monocytes (CD11b+Ly6gloLy6chi) and tumor-associated CD163+ macrophage frequencies were significantly decreased in both models. In addition, circulating CD4+ T cells and neutrophils (CD11b+Ly6g+Ly6cint) frequencies were also decreased in the 4T1 model. Others have shown that myeloid-derived suppressive cells (MDSC: CD11b+, Ly6gloLy6chi,IAIE-) play an important role in cancer metastasis. Our result suggests that soluble S100A4 protein promotes MDSC polarization or survival in the tumor, peripheral blood, and metastatic lung tissues. These findings strongly suggest that S100A4-11 could be used to block metastasis. We are currently testing the humanized S1004-11 antibody in preparation for clinical studies with this novel immune modulator. Citation Format: Jia-Shiun Leu, Hui Deng, Han Nhat Tran, Jose Maria Salazar, Jose A. Maldonado, Carlo D. Cristobal, Xiong Wei, Hyun-Kyoung Lee, Zhiqiang An, Ningyan Zhang, Kyuson Yun. A humanized therapeutic antibody against S100A4 as a novel immune modulator and an inhibitor of cancer metastasis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2948.
29
Han, Li, Lei Dong, Keith Leung, Zhicong Zhao, Yangchan Li, Ying Qing, Jianhuang Xue, et al. "Abstract 3617: METTL16 drives leukemogenesis and maintains leukemia stem cell self-renewal via reprogramming BCAA metabolism." Cancer Research 82, no. 12_Supplement (June 15, 2022): 3617. http://dx.doi.org/10.1158/1538-7445.am2022-3617.
Full textAbstract:
Abstract Background: As the most prevalent internal decorations in mammalian mRNA, N6-methyladenosine (m6A) has been reported to be involved in many physiological and pathological processes, including acute myeloid leukemia (AML). METTL3 and METTL14, the well-recognized m6A methyltransferase complex, contribute to AML. METTL16 is a recently identified m6A methyltransferase that has been reported to deposit m6A in a few targets. While, unlike METTL3/14, the biological functions of METTL16 are largely unknown. Here, we explored the function and mechanism of METTL16 in AML pathogenesis and evaluated its therapeutic potential for AML treatment. Methods: We performed CRISPR-Cas9 screen to evaluate the dependency of METTL16 in AML cells. We created METTL16 knockout (KO) cells and conditional KO mice to evaluate its role in leukemogenesis and normal hematopoiesis. We employed bone marrow transplantation (BMT), xenograft, and AML patient-derived xenograft (PDX) models to determine its role in AML development and progression. To identify the targets of METTL16, we performed m6A-seq and RNA-seq, followed m6A-qPCR, CLIP-qPCR, in vitro methyltransferase assays and RNA stability assays. To examine the effect of METTL16 on branched chain amino acid (BCAA) metabolism, we performed metabolic profiling with 13C, 15N-leucine. Results: CRISPR-Cas9 screen showed METTL16 is one of the most essential genes for the survival of AMLs. The AML cells display more robust dependency on METTL16 than METTL3/14. We found METTL16 is highly expressed in AML patients compared to healthy controls. METTL16 KO significantly inhibited AML cell proliferation, promoted cell apoptosis and myeloid differentiation in vitro, which could be totally reversed by forced expression of wild-type METTL16, but not catalytic-dead mutant. METTL16 depletion dramatically inhibited AML progression and prolonged survival of recipient mice in the BMT, xenograft and PDX models. In addition, METTL16 is highly expressed in LSCs contrast to leukemic bulk cells and METTL16 KO significantly attenuates LSC self-renewal in vitro and in vivo. By contrast, the role of METLL16 is largely spared in normal hematopoietic cells. Via integrated analysis of m6A-seq data and RNA-seq data, we identified two bona fide targets of METTL16, BCAT1 and BCAT2, which encode two critical BCAA transaminases in BCAA biosynthesis pathway. METTL16 promotes the expression of BCAT1 and BCAT2 via an m6A dependent manner. Metabolomics with 13C, 15N-leucine tracing showed that METTL16 KO results in suppressed pools of TCA cycle intermediates, some non-essential amino acids and nucleotides. Conclusion: We uncover a tumor-promoting role of METTL16 in AML and LSC self-renewal via reprogramming BCAA metabolism, in which METTL16 functions as an m6A methyltransferase to regulate expression of BCAT1 and BCAT2. Our data suggest that METTL16 is an attractive target for AML therapy. Citation Format: Li Han, Lei Dong, Keith Leung, Zhicong Zhao, Yangchan Li, Ying Qing, Jianhuang Xue, Chao Shen, Zhenhua Chen, Lei Gao, Kitty Wang, Keren Zhou, Wei Li, Brandon Tan, Zheng Zhang, Xi Qin, Rui Su, Xiaolan Deng, Jianjun Chen. METTL16 drives leukemogenesis and maintains leukemia stem cell self-renewal via reprogramming BCAA metabolism [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3617.
30
Hawkes, Eliza A., Kate Manos, Geoff Chong, Jodie Palmer, Michael MacManus, Colm Keane, Andrew Scott, et al. "Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The RaDD Study." Blood 134, Supplement_1 (November 13, 2019): 5328. http://dx.doi.org/10.1182/blood-2019-122635.
Full textAbstract:
Background: Although ~60% of patients with DLBCL are cured with frontline therapy, outcomes for those with relapsed/refractory disease remain poor. Tumour cells exploit immune checkpoint pathways, including the PD1/PDL1 axis, to evade and inhibit host anti-tumour immune responses. PD1/PDL1 expression and cytogenetic 9p24 alterations in some DLBCL subtypes provide additional rationale for PDL1 inhibition (PD-L1i) in DLBCL. Though single agent PD1i yields a disappointing ORR of 10-30% in heavily pre-treated DLBCL, some responses are durable.1 Radiotherapy (RT) is an established mechanism of stimulating anti-tumour immunity via increased circulating tumour antigen, immunogenic cell death and T-cell recruitment and activation in the tumour microenvironment. Synergy between concomitant immune checkpoint inhibition (ICI) and RT has been demonstrated in preclinical studies2 and solid tumours; a recent study in non-small cell lung cancer demonstrated an ORR of 36% with pembrolizumab + RT compared with 18% with pembrolizumab alone.3 RT hypofractionation appears critical to the abscopal effect when used with ICI,4 and concurrent RT and PD-L1i is more successful than sequential treatment.5 RT to multiple sites may broaden the spectrum of tumour antigen released and overcome clonal variation between disease sites; a dose-response relationship between RT and antigen release has yet to be established. This phase I study aims to determine the safety profile of escalating dose and number of sites of RT in combination with Durvalumab (MEDI4736), an anti-PD-L1 monoclonal antibody, in relapsed/refractory DLBCL, including primary refractory DLBCL and transformed follicular lymphoma. Study Design and Methods: RaDD (NCT03610061) includes eligible pts who have received ≥1 prior line of therapy and are ineligible for or relapsed after autologous stem cell transplantation (SCT). Pts with active autoimmune disease, CNS involvement, prior allogeneic SCT or chronic steroid use are excluded. Treatment comprises external beam RT to target site(s) daily for 5 days (Fig 1). Durvalumab 1500mg IV commences on day 2 of RT and continues 4-weekly until disease progression. Pts can continue until a second radiological progression if clinical benefit is ongoing. The primary endpoint is the toxicity, drug pharmacokinetics, maximum tolerated dose (MTD) and recommended phase two dose (RP2D) of simultaneous RT plus durvalumab. Secondary endpoints are response rates; progression free survival; and overall survival. An exploratory PET substudy will employ novel tracers to characterise the local and systemic immune response via assessment of the biodistribution of durvalumab (with 89Zr-Durvalumab) and CD8+ T cells (with 89Zr -Df-IAB22M2C). Biomarker sample collection is synchronised with PET response assessment. A comprehensive translational substudy will apply high throughput technologies to tissue and sequential blood samples to characterise the tumour-immune system interaction and correlate novel host, tumour and tumour microenvironment factors with treatment responses and toxicity. Findings may inform the RP2D. RT dose and site escalation will proceed according to a 3+3 design with 5 dose levels (cohorts 1-5, Fig 2). The dose limiting toxicity assessment window is the first 28 days. Projected enrolment for determination of MTD and RP2D is 6-30 pts pending toxicity. Recruitment will continue to a total of 36 pts to allow for secondary endpoint analysis. 5 pts have been enrolled to date. Acknowledgements: Victorian Cancer Agency (funding), Astra Zeneca (durvalumab and funding), Celgene (funding), Imaginab (89Zr -Df-IAB22M2C) References: 1. Ansell SM et al. Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation. J Clin Oncol. 2. Deng L et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 3. Theelen W et al. Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer. JAMA oncology. 4. Golden EB et al. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res. 5. Sharabi AB et al. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncology. Disclosures Hawkes: Janssen-Cilag: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Merck Sharp & Dohme: Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Research Funding, Speakers Bureau; Roche: Research Funding; Takeda: Speakers Bureau; Astra Zeneca: Research Funding; Merck KgA: Research Funding; Mundi pharma: Research Funding; Gilead: Membership on an entity's Board of Directors or advisory committees, Research Funding; Roche/Genentech: Membership on an entity's Board of Directors or advisory committees, Other: Travel expenses, Speakers Bureau. Manos:Janssen: Honoraria; Novo Nordisk Pharmaceuticals: Other: Travel. Chong:Merck Serono: Research Funding; Hutchison Medipharma: Research Funding; Pharmacyclics: Research Funding; Novartis: Research Funding; Bayer: Research Funding; BMS: Research Funding. MacManus:National Health and Medical Research Council Australia: Research Funding. Keane:MSD: Consultancy; Celgene: Consultancy; Gilead: Consultancy; BMS: Research Funding; Roche: Consultancy, Other: Travel Grant. Scott:Cancer Council Victoria: Research Funding; Cancer Australia: Research Funding; Avipep: Consultancy; IBA: Consultancy; Paracrine Therapeutics: Equity Ownership, Patents & Royalties; Life Science Pharmaceuticals: Equity Ownership; NHMRC: Research Funding; Abbvie: Consultancy, Patents & Royalties; Cure Brain Cancer: Research Funding; Medimmune: Consultancy; Humanigen: Patents & Royalties. Shortt:Celgene: Consultancy, Speakers Bureau; BMS: Consultancy, Speakers Bureau; Novartis: Consultancy, Speakers Bureau; Astex: Research Funding; Amgen: Research Funding; Gilead: Speakers Bureau; Takeda: Speakers Bureau. Ritchie:Amgen: Consultancy, Honoraria, Research Funding; Pfizer: Consultancy; BMS: Research Funding; Takeda: Research Funding; Beigene: Research Funding; Imago: Research Funding; Novartis: Honoraria; Sanofi: Honoraria. Lee:Australian Nuclear Science and Technology Organisation: Membership on an entity's Board of Directors or advisory committees. Koldej:NanoString Technologies: Other: Travel grant. OffLabel Disclosure: Durvalumab is an anti-PD-L1 monoclonal antibody.
31
Song, Yuanbin, Liang Shan, Rana Gbyli, Wei Liu, Xiaoying Fu, Xiaman Wang, Ashley Qin, et al. "In Vivo reconstruction of Human Erythropoiesis with Circulating Mature Human RBCs in Humanized Liver Mistrg Mice." Blood 134, Supplement_1 (November 13, 2019): 338. http://dx.doi.org/10.1182/blood-2019-130701.
Full textAbstract:
The murine host has remained a readily available and ethically acceptable model for the study of human diseases and therapeutic testing. Immunodeficient mouse models support engraftment of human hematopoietic stem cells (HSC) but with limitation in efficiency and mature lineage representation. Combined knock-in of several non-crossreactive human cytokines (M-CSF, IL3/GM-CSF, and Thrombopoietin) into the corresponding murine loci in the SRG strain (in short termed "MISTRG") has enhanced engraftment and maintenance of human HSCs with multi-lineage differentiation (Rongvaux et al. Annu Rev Immunol 2013, Deng et al. Nature 2015, Saito et al. Blood 2016, Theocharides et al. Haematologica 2016). Despite robust HSC engraftment and myelo- and erythropoiesis in bone marrow (BM), all humanized immunodeficient mouse models lack of mature human red blood cells (RBC), platelets, and myeloid cells in peripheral blood (PB) (Rahmig et al. Stem Cell Reports 2016, Yurino et al. Stem Cell Reports 2016, Song et al. Nat Commun 2019). Yet, full maturation and representation of all myeloid lineages in PB is essential to study diseases of the HSC, such as MDS, and of the RBC, such as sickle cell anemia or malaria. With universal absence of a murine adaptive immune system the culprit is likely the murine host's innate immune system. Previous studies have shown that treatment of engrafted mice with liposomal clodronate that abrogates murine (and human) macrophages, with or without cobra venom factor that eliminates complement, can increase mature human circulating RBC, but only transiently and with significant toxicity. We first sought to determine the site of huRBC sequestration and destruction. Intravital imaging after injection of CFSE labelled huRBC identified the murine liver as the major site of RBC destruction. While muRBC rapidly circulate through the liver circulation, huRBC have greatly increased transit times and are sequestered in liver vessels. We hypothesized that humanization of the murine host's liver could potentially alleviate huRBC sequestration and significantly increase circulating huRBC. In previous studies deletion of fumarylacetoacetate hydrolase (Fah) in the Rag-/-Il2rg-/- background has allowed humanization of the liver and served to study diseases such as malaria (Vaughan et al. J Clin Invest 2012). The liver is the site of synthesis of numerous proteins, some of which directly impact hematopoiesis and blood cells, such as complement. We deleted the Fah gene via CRISPR/Cas9 in MISTRG mice and crossed MISTRG-Fah-/- mice to homozygosity (MISTRGFah). MISTRGFah are viable, fertile, and healthy when maintained on drinking water supplemented with 2-(2-nitro-4-trifluoromethylbenzoyl)-1, 3-cyclohexanedione (NTBC), that blocks tyrosine metabolism upstream of Fah and prevents buildup of hepatotoxic metabolites. At 8 weeks of age we implanted MISTRGFah mice with commercially available, adult human hepatocytes (HuHep) via direct injection into the splenic vein, followed by gradual withdrawal of NTBC water. Regulated buildup of intracellular fumarylacetoacetate results in death of murine Fah-/- hepatocytes and regeneration with HuHep with up to 90% repopulation by HuHep (Azuma et al. Nature biotechnology 2007). When plasma human albumin levels reached 2mg/dL, indicative of significant (~80%) HuHep repopulation, we sublethally (80cGy) irradiated HuHepMISTRGFah mice and engrafted each mouse with 105 fetal liver (FL) derived CD34+ cells. 10 weeks post transplantation, mice were analyzed for engraftment and specifically erythroid maturation in PB. HuHepMISTRGFah mice had significantly higher levels of BM and interestingly spleen erythropoiesis and circulating huRBC in PB (Fig.1 a). CD235a+ huRBC in HuHepMISTRGFah mice are enucleated (Hoechst neg) and mature as evident by loss of CD49d (ITGA4) and gain of Band3 staining (Hu et al. Blood 2013) (Fig.1 b). Interestingly, human erythroid cells in MISTRG but not HuHepMISTRGFah mice are coated with murine complement C3 (muC3) (Fig.1 c) suggesting that liver humanization results in loss of muC3 expression. In conclusion, we have generated the first humanized mouse model with fully mature, circulating huRBC when engrafted with human CD34+ stem and progenitor cells. Ongoing studies are testing the applicability of this model to MDS and sickle cell disease. Disclosures Flavell: SMOC: Equity Ownership; Zai labs: Consultancy; GSK: Consultancy; Artizan Biosciences: Equity Ownership; Troy: Equity Ownership; Rheos Biomedicines: Equity Ownership.
32
Leggatt, Gary, Christine Gast, Rodney Gilbert, Kristin Veighey, Tahmina Rahman, and Sarah Ennis. "MO048PATHOGENIC VARIANTS IN CHLORIDE VOLTAGE-GATED CHANNEL 5 (CLCN5), ASSOCIATED WITH DENT DISEASE TYPE 1, SHOULD BE CONSIDERED IN END-STAGE KIDNEY DISEASE OF UNKNOWN AETIOLOGY." Nephrology Dialysis Transplantation 36, Supplement_1 (May 1, 2021). http://dx.doi.org/10.1093/ndt/gfab080.0020.
Full textAbstract:
Abstract Background and Aims Hemizygous variants in chloride voltage-gated channel 5 (CLCN5) on chromosome Xp11.22 cause Dent disease type 1, characterised by low-molecular-weight proteinuria, hypercalciuria, nephrocalcinosis, nephrolithiasis, and progressive renal failure. We describe a truncating pathogenic variant in two brothers presenting with end-stage kidney disease (ESKD) and no evidence of nephrolithiasis or nephrocalcinosis. Method Two white British brothers presented to a different regional centre over 20 years ago with ESKD of unknown aetiology. The UK 100,000 Genomes Project provided a unique opportunity to make a molecular diagnosis using whole-genome sequencing linked to clinical records. Results The older brother presented with ESKD aged 23 with bilateral small kidneys and no evidence of nephrolithiasis or nephrocalcinosis on ultrasound. He had various musculoskeletal pains, 'cutaneous ectopic calcification' and secondary hyperparathyroidism, all of which improved post parathyroidectomy. Investigation of his 17-year-old brother for consideration of kidney transplant donation revealed progressive chronic kidney disease (CKD), microscopic haematuria, proteinuria (3g/24hours) and hypokalaemia. There was no nephrocalcinosis or renal calculi on ultrasound or cystoscopy. Renal biopsy showed tubulointerstitial changes with patchy fibrosis and marked chronic inflammatory cell infiltrates. He had a history of enuresis, polydipsia, delayed bone age and general developmental delay. ESKD by the age of 22 was complicated by hypertension and hyperparathyroidism requiring parathyroidectomy. Right knee pain with 'unusual osteochondral abnormality' on MRI resulted in a supracondylar femoral osteotomy. Early serum and urine biochemistry results were not available. A hemizygous nonsense variant p.Arg417Ter in CLCN5 was identified by whole-genome sequencing via the 100,000 Genomes Project. Sanger sequencing at the Wessex Regional Genetics Laboratory confirmed this. This variant was predicted to be protein-truncating, was absent in the genome aggregation database (gnomAD) and equivalent to a variant associated with Dent disease in other patients therefore classified as a class 5 pathogenic variant according to ACMG guidelines. Three male children with Dent disease have previously been reported with the pathogenic variant p.Arg347Ter. A seven and a twelve year old from two different families in Japan had microscopic haematuria, proteinuria, elevated β2-microglobulin and normal renal function. The twelve-year-old had mild hypercalciuria, but neither had a history of nephrolithiasis or nephrocalcinosis. A four-year-old Turkish boy manifested hypophosphataemia, nephrolithiasis and nephrocalcinosis. Unusually for Dent disease, he also had hypokalaemic hypochloraemic metabolic alkalosis and hyper-reninaemic hyperaldosteronism more characteristic of Bartter syndrome, but with elevated β2-microglobulin more typical of Dent disease. None of these cases had CKD but were all reported at a very young age. Conclusion Approximately 15% of patients with ESKD in Europe have an unknown aetiology. Dent disease has a variable phenotype and screening of patients for low molecular weight proteinuria such as β2-microglobulin is not routinely performed. Dent disease type 1 should be considered in patients presenting with unexplained renal failure even without typical clinical features.
33
Prikhodina, Larisa, Papizh Svetlana, Natalia Mironenko, and Michael Ludwig. "FP805CARDIAC ARRHYTHMIAS IN BOYS WITH DENT DISEASE: SINGLE-CENTER EXPERIENCE." Nephrology Dialysis Transplantation 34, Supplement_1 (June 1, 2019). http://dx.doi.org/10.1093/ndt/gfz106.fp805.
Full text
34
Ceol, Monica, Lisa Gianesello, Giovanna Priante, Dorella Del Prete, and Franca Anglani. "FO069GENETIC ANALYSIS IN DENT DISEASE AND FUNCTIONAL STUDIES OF CLCN5 MUTATIONS IN PATIENTS’ KIDNEY BIOPSIES." Nephrology Dialysis Transplantation 34, Supplement_1 (June 1, 2019). http://dx.doi.org/10.1093/ndt/gfz096.fo069.
Full text
35
Bamgbola, Oluwatoyin Fatai, and Youssef Ahmed. "Differential diagnosis of perinatal Bartter, Bartter and Gitelman syndromes." Clinical Kidney Journal, October 25, 2020. http://dx.doi.org/10.1093/ckj/sfaa172.
Full textAbstract:
Abstract The common finding of hypokalemic alkalosis in several unrelated disorders may confound the early diagnosis of salt-losing tubulopathy (SLT). Antenatal Bartter syndrome (BS) must be considered in idiopathic early-onset polyhydramnios. Fetal megabladder in BS may allow its distinction from third-trimester polyhydramnios that occurs in congenital chloride diarrhea (CCD). Fetal megacolon occurs in CCD while fecal chloride >90 mEq/L in infants is diagnostic. Failure-to-thrive, polydipsia and polyuria in early childhood are the hallmarks of classic BS. Unlike BS, there is low urinary chloride in hypokalemic alkalosis of intractable emesis and cystic fibrosis. Rarely, renal salt wasting may result from cystinosis, Dent disease, disorders of paracellular claudin-10b and Kir4.1 potassium-channel deficiency. Acquired BS may result from calcimimetic up-regulation of a calcium-sensing receptor or autoantibody inactivation of sodium chloride co-transporters in Sjögren syndrome. A relatively common event of heterozygous gene mutations for Gitelman syndrome increases the likelihood of its random occurrence in certain diseases of adult onset. Finally, diuretic abuse is the most common differential diagnosis of SLT. Unlike the persistent elevation in BS, urinary chloride concentration losses waxes and wanes on day-to-day assessment in patients with diuretic misuse.
36
Serigne, Gueye, Kane Yaya, Seck Sidy Mouhamed, Chauveau Dominique, Lemrabott Ahmed Tall, Faye Maria, Cisse Mouhamadou Moustapha, et al. "Dent disease: About 4 Adult Observations Monitored in the Department of Nephrology and Organ Transplantation of Toulouse, France." Journal of Clinical & Experimental Nephrology 01, no. 03 (2016). http://dx.doi.org/10.21767/2472-5056.100017.
Full text
37
Rusu, Elena Emanuela, Adrian Catalin Lungu, Gabriel-Robert Pandele, Alexandru Iordache, Raluca Bobeica, Lucia Mihaela Ciobotaru, Sonia Balanica, et al. "#3320 GENETIC TESTING FOR MOLECULAR DIAGNOSIS OF NEPHROLITHIASIS AND NEPHROCALCINOSIS IN ADULT PATIENTS: A SINGLE-CENTER COHORT." Nephrology Dialysis Transplantation 38, Supplement_1 (June 2023). http://dx.doi.org/10.1093/ndt/gfad063c_3320.
Full textAbstract:
Abstract Background and Aims Hereditary factors represent an important cause of nephrolithiasis which will generate stone disease in adult. Molecular analysis in patients with nephrolithiasis (NL) and/or nephrocalcinosis (NC) for a genetic mutation has become more accessible and the benefits are highlighted by an increasing number of publications. The aim of the paper was to study genetic screening for 36 NL and/or NC patients in order to identify the cases that can be confirmed by mutations in known kidney stone genes. Method Between 2020–2022 we included 35 adult patients with NL/NC with onset on pediatric age or in young adults, plus one of the following criteria: family history for NL/NC, indicative phenotype, recurrent NL. All the patients were diagnosed with NL and/or NC by ultrasound or computed tomography scan. Inform consent was signed and dated before blood samples and we performed genetic testing using nephrolithiasis panel (that include 45 genes) from 2 laboratories. In addition, we performed clinical assessment in a multidisciplinary team, underwent metabolic assessment, and caring out the genealogical tree. Results The study included 18 females and 17 males. The mean age of studied patients was 34.9 ± 10.3 years (range 18 – 54 years), although mean age of NL/NC diagnosis was 19.4 ± 12.0 years (range 0.5 – 34 years). 29 patients presented NL of any type, 12 patients presented both NL and NC, and 3 patients isolated NC. All the patients presented positive family history of NL/NC, 17 (48.5%) patients had pediatric age of onset, 17 (48.5%) patients presented indicative phenotype and 19 (54.2%) recurrent stone disease. Causative monogenic mutations were detected in 25 of 35 NL/NC. We identified 20 deleterious variants in 12 out of 45 analyzed genes. Genetic testing was positive with a definite diagnosis (had pathogenic variant) in 17 (48.6%) of cases, while 3 (8.6%) patients presented likely pathogenic variants, and 5 (14.3%) patients had variants of uncertain significance (VUS). In our cohort, the most common cause of kidney stone disease was cystine nephrolithiasis in 8 (22.8%) patients, followed by hereditary distal renal tubular acidosis in 4 patients, Dent disease in 3 patients, primary hyperoxaluria type 1 in 2 patients, familial hypomagnesaemia with hypercalciuria and nephrocalcinosis in 2 patients. Other causes of kidney stone disease included: renal hypouricemia type 1, hereditary hypophosphatemic rickets with hypercalciuria, primary mitochondrial disorders, autosomal dominant familial idiopathic hypercalciuria, Bartter syndrome type 3, and autosomal dominant tubulo-interstitial disease with hyperuricemia. Pathogenic mutations were detected in the following 5 dominant disease genes: SLC7A9 (4 patients), SLC4A1 (3 patients), ADCY10 (1 patient), HNF1B (2 patients), POLG (1 patient). Also, we identified pathogenic mutations in the following 7 recessive disease genes: CLCN5 (3 patients), AGXT (2 patients), CLDN16 (2 patients), SLC3A1 (3 patients), SLC34A3 (1 patient), WDR72 (1 patient), CLCNKB (1 patient). The mean eGFR for the study group was 71.2 ± 37.6 ml/min/1.72 m2. Seventeen patients presented eGFR < 60 ml/min/1.73 m2: seven patients CKD stage 3, four patients CKD stage 4, two patients CKD stage 5, and two patients were with renal replacement therapy. Conclusion Genetic kidney stone disease is an underdiagnosed condition. Although 48.5% of the patients had NL/NC onset on pediatric age, the molecular diagnosis was performed in adulthood, and, for some of them, when they suffer of advanced kidney disease. In our cohort, genetic testing had a high rate of positive molecular diagnosis of NL/NC due to selection criteria. Five of our patients presented VUS, but with disease-specific phenotype. We emphasize the importance of reporting these cases to generate additional evidence that could allow the reclassification of these variants. We conclude that the molecular diagnosis improves patient management, prevent or delay chronic kidney disease, offer possibility of genetic counseling and an extended screening to the family. Thus, our study showed the potential benefits of genetic testing, especially in high-risk groups for stone disease.
38
Bhat, Dr Sanjay, and Anupma Kaul. "MO118ROLE OF DUAL ENERGY COMPUTED TOMOGRAPHY IN PREDICTING THE CHEMICAL COMPOSITION OF STONES." Nephrology Dialysis Transplantation 36, Supplement_1 (May 1, 2021). http://dx.doi.org/10.1093/ndt/gfab107.007.
Full textAbstract:
Abstract Background and Aims Dual-energy CT (DECT) has shown excellent outcomes in differentiating the chemical composition of the urinary stones with a great accuracy. A reliable determination of the chemical type of the stone help the clinician to better satisfy treatment options for the patient- medical versus surgery We used the DECT in our study to assess the accuracy of non-invasive differentiation of renal stones using the 3rd generation dual-source computed tomography (CT) scanner in determining the chemical composition of renal stones and to determine appropriate management based on DECT determined chemical composition of stones. Method This prospective study was conducted in the Department of surgery and radiodiagnosis and Imaging, Era Medical College and RML institute of Medical Sciences , Lucknow over the study period, i.e., November 2016 to May 2018 . The patients were those referred for non-contrast/contrast CT for the diagnosis/evaluation of urolithiasis from the department of Surgery admitted for PCNL/ESWL/therapeutic ureterorenoscopy. DECT ratios of the various stones were noted and compared with the post extraction analysis of stones for composition. A total of 100 patients were included in the study, and their DECT results were compared with the post-extraction analysis (by infrared spectroscopy as the standard comparative method). Results Mean age of patients was 41.15+/- 10.08 years with 64% being males. DECT was highly sensitive and specific in the diagnosis of various types of calculi based on their dual-energy ratio. It was found to be 100% sensitivity and 97.2% specificity for differentiating UA stones with level of agreement between chemical and DECT was almost perfect (k= .951) .However for hydroxyapatite stones was substantial (k=.889). Most of the stones belonged to non-UA category (72%), and only 28% were UA calculi. The sensitivity and specificity in differentiating a calcium oxalate from non-calcium oxalate calculus was 94.1% and 95.5%, respectively. Conclusion DECT highly sensitive and effective in characterizing chemical composition of the urinary stones and can help in determining the management plan and reduce the unnecessary burden of surgical interventions.
39
Barbaro, Federico, Andrea Tringali, Alberto Larghi, Anna Baldan, Graziano Onder, Pietro Familiari, Ivo Boškoski, Vincenzo Perri, and Guido Costamagna. "Endoscopic management of non‐anastomotic biliary strictures following liver transplantation: Long‐term results from a single‐center experience." Digestive Endoscopy, December 8, 2020. http://dx.doi.org/10.1111/den.13879.
Full text
40
Quirino, Lilian Caldas, Pedro Henrique de Azambuja Carvalho, Audrey Foster Lefort Rocha, Marisa Aparecida Cabrini Gabrieli, and Valfrido Antonio Pereira-Filho. "Autogenous Dental Transplantation in a Patient Undergoing Class III Dento-Facial Deformity." Journal of Craniofacial Surgery Publish Ahead of Print (July 3, 2020). http://dx.doi.org/10.1097/scs.0000000000006668.
Full text
41
Jang, Sung Ill, Tae Ryong Chung, Jae Hee Cho, Kwang‐Hun Lee, Seung‐Moon Joo, Jung Hye Choi, Sae In Kim, and Dong Ki Lee. "Short fully covered self‐expandable metal stent for treatment of proximal anastomotic benign biliary stricture after living‐donor liver transplantation." Digestive Endoscopy, November 24, 2020. http://dx.doi.org/10.1111/den.13871.
Full text
42
Høyer, Klaus Lindgaard. "Regulering af transplantation: Overvejelser om en teknologis moralske, politiske og økonomiske aspekter." Tidsskrift for Forskning i Sygdom og Samfund 6, no. 11 (November 29, 2009). http://dx.doi.org/10.7146/tfss.v6i11.2694.
Full textAbstract:
Denne artikel undersøger moralske, politiske og økonomiske aspekter af reguleringen af knogletransplantation. Der argumenteres for, at EU og den danske lovgivning søger at regulere gennem en relativt snæver, sundhedsfaglig forståelse af hvilken type viden, der er relevant for teknologiens praksis. Derved ignoreres en række faktorer, der har afgørende betydning for, hvad man gør i praksis. Desuden forbigås en række moralske implikationer af teknologien og dens regulering. En større forståelse for, hvad der er på spil for sundhedsprofessionelle og patienter kan måske skabe bedre sammenhæng mellem den regulering, der foregår på papiret, og det man i praksis foretager sig.
43
Iwashita, Takuji, Yuhei Iwasa, and Masahito Shimizu. "Multiple transluminal gateway technique with transplantation of lumen‐apposing metal stent for direct endoscopic necrosectomy in a patient with infected walled‐off pancreatic necrosis." Digestive Endoscopy, June 15, 2021. http://dx.doi.org/10.1111/den.14014.
Full text
44
"Discoveries and Innovations in Drug Development (Vol. 26, No. 1, Full Issue)." Asia-Pacific Biotech News 26, no. 01 (December 28, 2021). http://dx.doi.org/10.1142/s0219030322000015.
Full textAbstract:
For the month of January 2022, APBN looks at some discoveries and innovation in pharmacology. In Features, Dr Harish Dave, Co-Founder and Chief Medical Officer of AUM Biosciences, discusses today's shifting paradigm in oncology drug development towards highly selective, minimally toxic, and patient-centric treatments, while Jade Pallett, Chief Technology Officer for Zoono UK & Europe, sheds light on how antimicrobial coatings outdo traditional methods of disinfection. Then, we have A/Prof Alexandra Sharland, Dr Nicole Mifsud, and Eric Son to elucidate how understanding antigen-specificity of host T cells can reduce organ transplantation rejection. Finally, in Spotlights, we have two interviews – one where we speak to Mr Willson Deng, CEO of Arcstone, on the role of digital technology in supporting MedTech manufacturing, and the other with Liu Qun, Head of IQVIA, China, where we learn more about the Chinese biopharmaceutical market.
45
Ginsberg, Charles. "The Influence of Medical School Debt on Career Choices in Nephrology." Clinical Journal of the American Society of Nephrology, December 7, 2020, CJN.14260920. http://dx.doi.org/10.2215/cjn.14260920.
Full text
46
Natali, B. M., F. M. Righini, M. Cameli, C. Sciaccaluga, S. Bernazzali, M. Maccherini, D. Menci, F. D"ascenzi, M. Focardi, and S. Mondillo. "P890 Heart transplantation and antibody-mediated rejection: role of the strain as an early marker of cardiac dysfunction in patients with anti-HLA antibody." European Heart Journal - Cardiovascular Imaging 21, Supplement_1 (January 1, 2020). http://dx.doi.org/10.1093/ehjci/jez319.530.
Full textAbstract:
Abstract Background Antibody-mediated rejection of the transplated heart is essentially diagnosed through endomyocardial biopsy whereas clinical elements, anti- Human Leukocite Antigens (HLA) antibody and graft dysfunction are supplementary components. Over the years, several studies have tried to define early diagnostic markers, but to date a univocal consensus has not been achieved. Purpose The aim of the study was to identify though a non-invasive technique, such as transthoracic echocardiography, early signs of impaired cardiac function in heart transplanted patients, in presence of anti-HLA antibodies but without any histological sign of antibody-mediated rejection, assessed through endomyocardial biopsy. Methods In the study 29 heart transplanted patients were enrolled, and they were divided into two groups ‘HLA+’ (15 patients) and ‘HLA-’ (14 patients), based on the presence and the absence of circulating anti-HLA antibodies, respectively. None of the patients had evidence of either coronary allograft vasculopathy or antibody-mediated rejection, attested by endomyocardial biopsy. Each patient underwent through echocardiographic exam, within one month from the biopsy, analysing standard parameters of both systolic and diastolic function, together with strain analysis of right and left ventricle (RV and LV) and left atrium (LA). Results Clinical and demographic characteristics did not different significantly between the two groups, and neither did standard echocardiographic parameters. The only significant parameter that show a statistically significant different was Deceleration Time of E wave (DecT E), which resulted to be lower in the ‘HLA+’ group. Regarding strain analysis, peak atrial longitudinal strain was significantly different between HLA+ and HLA- patients (10,9 ± 5,6 vs 14,9 ± 4,5; p < 0.005), whereas peak atrial contraction strain did not. The study attested a strong difference of both LV global longitudinal strain (- 20,2 ± 5,9 vs - 23,2 ± 3,3; p < 0.005) and RV strain between the two analysed subsets (-16,9 ± 3,4 vs -19,3 ± 3,1 p < 0.005). The figure shows the most significant correlations found in the study, respectively RV strain (on the left), LV strain (in the middle) and DecT E (on the right), the figures on top are representative of HLA- patients, whereas the ones at the bottom are representative of HLA+ patients. Conclusion The presence of circulating anti-HLA antibodies seems to be correlated with a mild cardiac dysfunction, even in the absence of antibody-mediated rejection. This subtle dysfunction is not completely detectable by standard echocardiographic parameters, whereas strain analysis has showed promising results since it revealed more clearly an impaired function of both ventricles in heart transplanted HLA+ patients, with potentially important clinical repercussion. Abstract P890 Figure.
47
Pomarico, Luciana. "CONHECIMENTOS E ATITUDES DE ACADÊMICOS E RESPONSÁVEIS SOBRE A UTILIZAÇÃO DO BANCO DE DENTES." Revista Fluminense de Odontologia, July 7, 2016. http://dx.doi.org/10.22409/ijosd.v1i45.329.
Full textAbstract:
RESUMO O objetivo foi avaliar conhecimentos e atitudes de acadêmicos e responsáveis quanto à utilização de dentes humanos. Foram aplicados 60 questionários, e, para análise dos dados, foi utilizado o programa SPSS 16.0. A maioria dos acadêmicos (96,7%) conhecia o banco de dentes, ao contrário dos responsáveis (10%) (p>0,05). A maior parte das amostras considerava importante a utilização dos dentes humanos para pesquisas. No entanto, quando questionados sobre utilização nos pacientes, 66,7% dos acadêmicos responderam negativamente. 96,7% dos responsáveis doariam os dentes dos filhos e 83,3% consentiriam autorização para realização de procedimentos. Concluiu-se que, apesar do conhecimento sobre o banco de dentes, os acadêmicos se mostraram receosos quanto à sua utilização. Ao contrário, a receptividade por parte dos responsáveis não seria obstáculo. PALAVRAS-CHAVE: Odontopediatria, Dente, Transplante de órgãos. ABSTRACT The objective was to assess knowledge and attitudes of students and caregivers regarding the use of human teeth. 60 questionnaires were applied. 60 questionnaires were applied, and data analysis was conducted using SPSS 16.0. Most students (96.7%) knew the bank of teeth, unlike those caregivers (10%) (p>0.05). Most of the sample felt it was important the use of human teeth for research. However, when asked about use in patients, 66.7% of the students responded negatively. 96.7% of parents donate their child's teeth and 83.3% consent authorization to perform procedures. It was concluded that despite the knowledge of the tooth bank, the students were concerned about their use. Instead, the receptivity of those caregivers would not be an obstacle. KEYWORDS: Pediatric dentistry, Tooth, Organ transplantation.
48
"A Correction to the Research Article Titled: "Inhibition of Transplantation Tolerance by Immune Senescence Is Reversed by Endocrine Modulation" by G. Zhao, D. J. Moore, J. I. Kim, K. M. Lee, M. R. O'Connor, P. E. Duff, M. Yang, J. Lei, J. F. Markmann, S. Deng." Science Translational Medicine 3, no. 114 (December 21, 2011): 114er10. http://dx.doi.org/10.1126/scitranslmed.3003577.
Full text